Skip to content
TriangleGet started
← Back to this collection

PUBLICATIONS · 16123223

Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Blood
Publication date
2005 Dec 1
First author
Hiddemann W

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships

    Authors and identifiers

    1. name
      Hiddemann W
      type
      Author
    2. name
      Kneba M
      type
      Author
    3. name
      Dreyling M
      type
      Author
    4. name
      Schmitz N
      type
      Author
    5. name
      Lengfelder E
      type
      Author
    6. name
      Schmits R
      type
      Author
    7. name
      Reiser M
      type
      Author
    8. name
      Metzner B
      type
      Author
    9. name
      Harder H
      type
      Author
    10. name
      Hegewisch-Becker S
      type
      Author
    11. name
      Fischer T
      type
      Author
    12. name
      Kropff M
      type
      Author
    Complete bibliographic record and source provenance
    authors
    1. name
      Hiddemann W
      type
      Author
    2. name
      Kneba M
      type
      Author
    3. name
      Dreyling M
      type
      Author
    4. name
      Schmitz N
      type
      Author
    5. name
      Lengfelder E
      type
      Author
    6. name
      Schmits R
      type
      Author
    7. name
      Reiser M
      type
      Author
    8. name
      Metzner B
      type
      Author
    9. name
      Harder H
      type
      Author
    10. name
      Hegewisch-Becker S
      type
      Author
    11. name
      Fischer T
      type
      Author
    12. name
      Kropff M
      type
      Author
    bibliography ids
    1. nci-bib-fa9e5c765f041091e74823fe
    book metadata
    content sha256
    f397075645af3e7a9b81ee2c79c108e241e0173d63489a0f8a06f4690784c218
    document type
    citation
    dois
    1. 10.1182/blood-2005-01-0016
    electronic publication date
    display
    2005 Aug 25
    precision
    day
    year
    2005
    evidence scope
    bibliographic_metadata_only
    id
    pubmed:16123223
    immutable id
    pubmed:16123223@f397075645af3e7a9b81ee2c79c108e241e0173d63489a0f8a06f4690784c218
    journal
    abbreviation
    Blood
    issn electronic
    Source null
    issn print
    0006-4971
    issue
    12
    name
    Blood
    nlm unique id
    7603509
    pages
    3725-32
    volume
    106
    languages
    1. eng
    notices
    absence is not clearance
    true
    has correction metadata
    false
    has expression of concern metadata
    false
    has retraction in link
    false
    pubmed marks article retracted
    false
    pubmed marks retraction notice
    false
    relationships
      outcomes validated
      false
      pmid
      16123223
      provenance
      batch id
      acd1a19ec1fd03e5b423
      provider
      NCBI PubMed ESummary
      record sha256
      ab68af1bfd833ee46f79e825115a154196078512da7805bb0236f0f82bcf793a
      response sha256
      06f2789b1faf1384eea463ec33b6ace6458084d0e39588df6f3b23cecac27647
      retrieved at
      2026-09-09T23:46:01.895425+00:00
      publication date
      display
      2005 Dec 1
      precision
      day
      year
      2005
      publication types
      1. Clinical Trial, Phase III
      2. Comparative Study
      3. Journal Article
      4. Multicenter Study
      5. Randomized Controlled Trial
      6. Research Support, Non-U.S. Gov't
      record status
      PubMed - indexed for MEDLINE
      schema version
      1.0
      source url
      https://pubmed.ncbi.nlm.nih.gov/16123223/
      title
      Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group.

      Preserved source evidence · Independent clinical review pending · Not medical advice